



Stanley F. Chavire

Member

Direct 781-697-2268

Fax 781-622-5933

Waltham, MA

schavire@morse.law

Dr. Stanley F. Chavire is a Registered Patent Attorney, specializing in patent prosecution, licensing of intellectual property and related counseling. Stan advises clients in developing and implementing strategies to protect their intellectual property, with a particular focus on clients in the life sciences industry.

Stan counsels clients with respect to the preparation and prosecution of utility patents and design patents, the evaluation of intellectual property portfolios and regulatory exclusivity matters. Stan also supports clients' domestic and international licensing initiatives by conducting in-depth due diligence evaluations and by negotiating and drafting a variety of license, development and supply agreements.

Prior to beginning his legal career Stan practiced as a Registered Pharmacist in both clinical and retail settings, advising physicians and patients with regard to the optimization of drug therapies, the identification and resolution of drug-drug and drug-disease state interactions, and performing drug utilization reviews.

Representative Matters

- Represented **Oscient Pharmaceuticals Corporation** in its \$78 million purchase of the U.S. rights to the cardiovascular drug Antara (fenofibrate) from Reliant Pharmaceuticals.
- Represented **Oscient Pharmaceuticals Corporation** in its acquisition of worldwide rights to Ramoplanin from Pfizer Inc. subsidiary Vicuron Pharmaceuticals Inc.
- Represented **Agrivida, Inc.** in its research alliance with Syngenta Ventures to develop advanced crop technology and provide Agrivida access to Syngenta crop technology and intellectual property.
- Represented **ETEX Corporation** in its sale to Zimmer Holdings, Inc.
- Represented **Curadel, Inc.** in its in-licensure of imaging technology from Beth Israel Deaconess Medical Center.

Education

Suffolk University Law School, J.D.

Massachusetts College of Pharmacy and Health Sciences, B.S., Pharm.D.

Admissions

Massachusetts Bar

U.S. Patent & Trademark Office

Practice Areas

Corporate

Intellectual Property

Licensing & Strategic Alliances

Patent

Industries

Educational Institutions & Hospitals

Life Sciences

Medical Devices

Software-as-a-Service

Recognition

- Represented **ProQR Therapeutics B.V.** in its in-licensure of technology from Massachusetts General Hospital for the treatment of cystic fibrosis.
- Represented **Virgin Pulse, Inc.** in its in-licensure of trademarks from Virgin Enterprises Limited.
- Represented **MacSpeech, Inc.**, a provider of speech recognition software, in its sale to Nuance Communications.
- Represented **Outside The Classroom, Inc.**, a provider of the largest online alcohol prevention course AlcoholEdu®, in its sale to EverFi, Inc.

Affiliations

Boston Patent Law Association (BPLA)

Boston Bar Association

Licensing Executives Society

Speaking Engagements

Panelist, *Show Me the Money: Bio Bucks, Royalties and Other Payment Structures in Strategic Alliances*

Speaker, *Cocktails & Conversation with Life Sciences Industry Leaders*, Mass Innovation Labs

Panelist, *Encore Event! Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series*

Panelist, *Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series – Panel 4*

Presenter, *Intellectual Property Approaches to Safeguard Value*, a Med DevGroup Boston forum

Presenter, *Legal Perspectives on Conducting Business in the U.S.*, swissnex Boston

Presenter, *ABC's for Life Sciences Entrepreneurs: From Start-Up to Exit*, CIC series

Presenter, *Pharmaceutical Patent Protection and Enforcement Conference* in Baltimore, Maryland

Presenter, *Power of Trade Secrets: When Not To Patent Your Invention*, Med Dev Group

Publications

Quoted, *Long-standing trademark question before Supreme Court*, Massachusetts Lawyers Weekly

Improved Forecast for IP Harvest: Gathering Seeds from USPTO Memo on Vanda

Sandoz Inc. v. Amgen Inc.: Supreme Court Clarifies BPCIA Provisions

Supreme Court Denies Sequenom's Petition to Clarify Scope of Mayo in *Sequenom v. Ariosa*

Global Medical Device Regulatory Strategy

A Tangled Web of Post-Patent Expiry Royalty Obligations

United States Completes Hague Agreement Deposit For Industrial Designs

Massachusetts Enacts Biosimilar Substitution Law



MA Rising Stars
2014 – 2015



FDA Revises Interpretation of 5-year NCE Exclusivity